# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

# RIMFROST AS Petitioner

v.

# AKER BIOMARINE ANTARCTIC AS Patent Owner

**CASE IPR: IPR2020-01534** 

U.S. Patent No. 10,010,567 B2

### PATENT OWNER'S SUR-REPLY TO PETITIONER'S REPLY

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450



## **TABLE OF CONTENTS**

I.	INTRODUCTION AND SUMMARY OF ARGUMENT	3
II.	COLLATERAL ESTOPPEL DOES NOT APPLY	4
III.	GROUND 1 SHOULD BE DENIED	5
V.	GROUNDS 2, 3 AND 4 SHOULD BE DENIED	18
VI.	CERTIFICATE OF COMPLIANCE	19
VII.	CONCLUSION AND PRECISE RELIEF REQUESTED	19
CER'	TIFICATE OF SERVICE	20



### I. INTRODUCTION AND SUMMARY OF ARGUMENT

All of the asserted Grounds rely on Bottino II for the "less than 3% w/w free fatty acids" limitation, including Ground 1 which is the Ground asserted against both independent claims (claims 1 and 15). The combined references in the Grounds fail to provide this claim element. As a result, Petitioner has failed to present any Grounds which establish a *prima facie* case of obviousness.

Petitioner continues to allege that the "unknown" fraction of the Station 11 krill extract of Bottino II (Ex. 1038) contained free fatty acids. Petitioner's Reply ("Reply"; Paper 14). There is no dispute that Bottino II discloses that the "unknown" fraction included unidentified lipids that migrate between diglycerides and triglycerides in the thin layer chomatography (TLC) method utilized by Bottino II. However, in continuing to make this argument, Petitioner ignores the the irrefutable evidence that in the TLC method used by Bottino II, based on the method of Freeman and West (Ex. 2002), free fatty acids <u>do not</u> have an R<sub>f</sub> between that of diglycerides and triglcyerides. Based on the only relevant evidence, the "unknown" fraction does not include free fatty acids.

In an attempt to direct attention away from this irrefutable evidence,  $Petitioner\ points\ to\ a\ number\ of\ other\ cherry-picked\ references\ that\ disclose\ TLC$  methods where free fatty acids do have an  $R_f$  between that of diglycerides and triglycerides. However, this approach is not scientifically valid as none of those



references use solvent systems that are the same as or similar to Bottino II or Freeman and West. Further, Petitioner and its expert have provided no supporting literature references or experimental evidence that shows that the slight changes between the Bottino II method and the Freeman and West method (*i.e.*, deletion of 0.2 parts acetic acid in solvent system 1 and use of a different silica gel) would have any impact on how free fatty acids migrate in relation to diglycerides and triglycerides as specifically disclosed in Freeman and West. Dr. Tallon's speculative expert testimony on this issue is unsupported by any evidence or record and should be ignored.

### II. COLLATERAL ESTOPPEL DOES NOT APPLY

Petitioner briefly addresses collateral estoppel at p. 4 of its Reply, alleging that the references in the Grounds had previously been considered by the Board. In making this argument, Petitioner for some reason focuses on the cholesterol limitation appearing in two of the dependent claims. This is an attempt to side-step the issue raised by Patent Owner in its Response (Paper 9; "PO Response") that both **independent** claims of the '567 patent include the limitation of "less than 3% w/w free fatty acids" which had not been previously addressed in any decision by the Board. PO Response at 10-12. As explained in the PO Response, this is a completely new claim element that has not been previously adjudicated and which



materially alters the question of invalidity. *Id.* at 11. Petitioner's attempt to redirect the Board's attention to a different claim limitation in the dependent claims regarding cholesterol both ignores Patent Owner's arguments which specifically apply the relevant standards for collateral estoppel and evidences a misunderstanding of the law of collateral estoppel. Indeed, Petitioner has made no attempt to address PO's arguments in its Response regarding the applicable elements for establishing whether collateral estoppel exists.

### III. GROUND 1 SHOULD BE DENIED

The Ground 1 combination of Sampalis II, Bottino II and Randolph does not teach or suggest the claim limitation of "less than 3% w/w free fatty acids" as required by both independent claims. As a result, Petitioner has failed to meet its burden of establishing a *prima facie* case of obviousness.

It cannot be disputed that Bottino II teaches that the data for the Station II krill lipid extract reported in Table 2 was obtained by TLC using the method of Freeman and West with three slight modifications: 1) the silica gel Adsorbosil-5 was used instead of silica gel-G; 2) 0.2 parts of acetic acid was eliminated from solvent mixture 1; and 3) gravimetry was used for quantitation of the spots



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

